ID   MP2K2_HUMAN             Reviewed;         400 AA.
AC   P36507;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   10-MAY-2017, entry version 197.
DE   RecName: Full=Dual specificity mitogen-activated protein kinase kinase 2;
DE            Short=MAP kinase kinase 2;
DE            Short=MAPKK 2;
DE            EC=2.7.12.2 {ECO:0000269|PubMed:10409742};
DE   AltName: Full=ERK activator kinase 2;
DE   AltName: Full=MAPK/ERK kinase 2;
DE            Short=MEK 2;
GN   Name=MAP2K2; Synonyms=MEK2, MKK2, PRKMK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8388392;
RA   Zheng C.-F., Guan K.-L.;
RT   "Cloning and characterization of two distinct human extracellular
RT   signal-regulated kinase activator kinases, MEK1 and MEK2.";
RL   J. Biol. Chem. 268:11435-11439(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Muscle, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   PROTEIN SEQUENCE OF 40-51; 53-61; 64-100; 102-112; 164-172; 194-205;
RP   265-297; 362-371 AND 389-397, PHOSPHORYLATION AT THR-394, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Colon carcinoma;
RA   Bienvenut W.V., Zebisch A., Kolch W.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [4]
RP   PROTEIN SEQUENCE OF 210-231, INACTIVATION BY YERSINIA YOPJ,
RP   PHOSPHORYLATION AT SER-222 AND SER-226, ACETYLATION AT SER-222 AND
RP   SER-226, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=17116858; DOI=10.1073/pnas.0608995103;
RA   Mittal R., Peak-Chew S.Y., McMahon H.T.;
RT   "Acetylation of MEK2 and I kappa B kinase (IKK) activation loop
RT   residues by YopJ inhibits signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:18574-18579(2006).
RN   [5]
RP   CLEAVAGE BY ANTHRAX LETHAL FACTOR.
RX   PubMed=9563949; DOI=10.1126/science.280.5364.734;
RA   Duesbery N.S., Webb C.P., Leppla S.H., Gordon V.M., Klimpel K.R.,
RA   Copeland T.D., Ahn N.G., Oskarsson M.K., Fukasawa K., Paull K.D.,
RA   Vande Woude G.F.;
RT   "Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal
RT   factor.";
RL   Science 280:734-737(1998).
RN   [6]
RP   PROTEIN SEQUENCE OF 39-49; 52-61 AND 352-361, CATALYTIC ACTIVITY,
RP   COFACTOR, INTERACTION WITH KSR1, SUBCELLULAR LOCATION, AND
RP   PHOSPHORYLATION AT SER-222.
RX   PubMed=10409742; DOI=10.1128/MCB.19.8.5523;
RA   Stewart S., Sundaram M., Zhang Y., Lee J., Han M., Guan K.L.;
RT   "Kinase suppressor of Ras forms a multiprotein signaling complex and
RT   modulates MEK localization.";
RL   Mol. Cell. Biol. 19:5523-5534(1999).
RN   [7]
RP   CLEAVAGE BY ANTHRAX LETHAL FACTOR.
RX   PubMed=11104681; DOI=10.1042/bj3520739;
RA   Vitale G., Bernardi L., Napolitani G., Mock M., Montecucco C.;
RT   "Susceptibility of mitogen-activated protein kinase kinase family
RT   members to proteolysis by anthrax lethal factor.";
RL   Biochem. J. 352:739-745(2000).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-293 AND SER-295, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-394 AND THR-396, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [13]
RP   INTERACTION WITH SGK1.
RX   PubMed=19447520; DOI=10.1016/j.jhep.2009.02.027;
RA   Won M., Park K.A., Byun H.S., Kim Y.R., Choi B.L., Hong J.H., Park J.,
RA   Seok J.H., Lee Y.H., Cho C.H., Song I.S., Kim Y.K., Shen H.M.,
RA   Hur G.M.;
RT   "Protein kinase SGK1 enhances MEK/ERK complex formation through the
RT   phosphorylation of ERK2: implication for the positive regulatory role
RT   of SGK1 on the ERK function during liver regeneration.";
RL   J. Hepatol. 51:67-76(2009).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-295 AND THR-394, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-394 AND THR-396, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-394 AND THR-396, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-23 AND THR-396, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [21]
RP   VARIANT CFC4 CYS-57.
RX   PubMed=16439621; DOI=10.1126/science.1124642;
RA   Rodriguez-Viciana P., Tetsu O., Tidyman W.E., Estep A.L., Conger B.A.,
RA   Cruz M.S., McCormick F., Rauen K.A.;
RT   "Germline mutations in genes within the MAPK pathway cause cardio-
RT   facio-cutaneous syndrome.";
RL   Science 311:1287-1290(2006).
RN   [22]
RP   VARIANTS CFC4 VAL-57 AND HIS-134.
RX   PubMed=18042262; DOI=10.1111/j.1399-0004.2007.00931.x;
RA   Schulz A.L., Albrecht B., Arici C., van der Burgt I., Buske A.,
RA   Gillessen-Kaesbach G., Heller R., Horn D., Hubner C.A., Korenke G.C.,
RA   Konig R., Kress W., Kruger G., Meinecke P., Mucke J., Plecko B.,
RA   Rossier E., Schinzel A., Schulze A., Seemanova E., Seidel H.,
RA   Spranger S., Tuysuz B., Uhrig S., Wieczorek D., Kutsche K., Zenker M.;
RT   "Mutation and phenotypic spectrum in patients with cardio-facio-
RT   cutaneous and Costello syndrome.";
RL   Clin. Genet. 73:62-70(2008).
RN   [23]
RP   VARIANT CFC4 GLN-128, AND CHARACTERIZATION OF VARIANT CFC4 GLN-128.
RX   PubMed=20358587; DOI=10.1002/ajmg.a.33342;
RA   Rauen K.A., Tidyman W.E., Estep A.L., Sampath S., Peltier H.M.,
RA   Bale S.J., Lacassie Y.;
RT   "Molecular and functional analysis of a novel MEK2 mutation in cardio-
RT   facio-cutaneous syndrome: transmission through four generations.";
RL   Am. J. Med. Genet. A 152:807-814(2010).
CC   -!- FUNCTION: Catalyzes the concomitant phosphorylation of a threonine
CC       and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP
CC       kinases. Activates the ERK1 and ERK2 MAP kinases (By similarity).
CC       {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:10409742}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:10409742};
CC   -!- SUBUNIT: Interacts with MORG1 (By similarity). Interacts with SGK1
CC       (PubMed:19447520). Interacts with KSR1 (PubMed:10409742).
CC       {ECO:0000250|UniProtKB:Q63932, ECO:0000269|PubMed:10409742,
CC       ECO:0000269|PubMed:19447520}.
CC   -!- INTERACTION:
CC       P10398:ARAF; NbExp=6; IntAct=EBI-1056930, EBI-365961;
CC       P15056:BRAF; NbExp=6; IntAct=EBI-1056930, EBI-365980;
CC       O95273:CCNDBP1; NbExp=3; IntAct=EBI-1056930, EBI-748961;
CC       Q12959:DLG1; NbExp=10; IntAct=EBI-1056930, EBI-357481;
CC       P04049:RAF1; NbExp=3; IntAct=EBI-1056930, EBI-365996;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10409742}.
CC       Membrane {ECO:0000269|PubMed:10409742}; Peripheral membrane
CC       protein {ECO:0000269|PubMed:10409742}. Note=Membrane localization
CC       is probably regulated by its interaction with KSR1.
CC       {ECO:0000269|PubMed:10409742}.
CC   -!- PTM: MAPKK is itself dependent on Ser/Thr phosphorylation for
CC       activity catalyzed by MAP kinase kinase kinases (RAF or MEKK1).
CC       Phosphorylated by MAP2K1/MEK1 (By similarity). {ECO:0000250}.
CC   -!- PTM: Acetylation of Ser-222 and Ser-226 by Yersinia yopJ prevents
CC       phosphorylation and activation, thus blocking the MAPK signaling
CC       pathway. {ECO:0000269|PubMed:17116858, ECO:0000269|Ref.3}.
CC   -!- DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: A
CC       form of cardiofaciocutaneous syndrome, a multiple congenital
CC       anomaly disorder characterized by a distinctive facial appearance,
CC       heart defects and mental retardation. Heart defects include
CC       pulmonic stenosis, atrial septal defects and hypertrophic
CC       cardiomyopathy. Some affected individuals present with ectodermal
CC       abnormalities such as sparse, friable hair, hyperkeratotic skin
CC       lesions and a generalized ichthyosis-like condition. Typical
CC       facial features are similar to Noonan syndrome. They include high
CC       forehead with bitemporal constriction, hypoplastic supraorbital
CC       ridges, downslanting palpebral fissures, a depressed nasal bridge,
CC       and posteriorly angulated ears with prominent helices.
CC       {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262,
CC       ECO:0000269|PubMed:20358587}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L11285; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; BC000471; AAH00471.1; -; mRNA.
DR   EMBL; BC018645; AAH18645.1; -; mRNA.
DR   CCDS; CCDS12120.1; -.
DR   PIR; A46723; A46723.
DR   RefSeq; NP_109587.1; NM_030662.3.
DR   UniGene; Hs.465627; -.
DR   PDB; 1S9I; X-ray; 3.20 A; A/B=55-400.
DR   PDB; 4H3Q; X-ray; 2.20 A; B=4-16.
DR   PDBsum; 1S9I; -.
DR   PDBsum; 4H3Q; -.
DR   ProteinModelPortal; P36507; -.
DR   SMR; P36507; -.
DR   BioGrid; 111591; 39.
DR   DIP; DIP-29119N; -.
DR   IntAct; P36507; 17.
DR   MINT; MINT-99667; -.
DR   STRING; 9606.ENSP00000262948; -.
DR   BindingDB; P36507; -.
DR   ChEMBL; CHEMBL2964; -.
DR   DrugBank; DB06616; Bosutinib.
DR   DrugBank; DB08911; Trametinib.
DR   GuidetoPHARMACOLOGY; 2063; -.
DR   iPTMnet; P36507; -.
DR   PhosphoSitePlus; P36507; -.
DR   SwissPalm; P36507; -.
DR   BioMuta; MAP2K2; -.
DR   DMDM; 547915; -.
DR   REPRODUCTION-2DPAGE; IPI00003783; -.
DR   EPD; P36507; -.
DR   MaxQB; P36507; -.
DR   PaxDb; P36507; -.
DR   PeptideAtlas; P36507; -.
DR   PRIDE; P36507; -.
DR   DNASU; 5605; -.
DR   Ensembl; ENST00000262948; ENSP00000262948; ENSG00000126934.
DR   GeneID; 5605; -.
DR   KEGG; hsa:5605; -.
DR   UCSC; uc002lzk.4; human.
DR   CTD; 5605; -.
DR   DisGeNET; 5605; -.
DR   GeneCards; MAP2K2; -.
DR   GeneReviews; MAP2K2; -.
DR   H-InvDB; HIX0033655; -.
DR   HGNC; HGNC:6842; MAP2K2.
DR   HPA; CAB003835; -.
DR   HPA; HPA051993; -.
DR   MalaCards; MAP2K2; -.
DR   MIM; 601263; gene.
DR   MIM; 615280; phenotype.
DR   neXtProt; NX_P36507; -.
DR   OpenTargets; ENSG00000126934; -.
DR   Orphanet; 1340; Cardiofaciocutaneous syndrome.
DR   Orphanet; 638; Neurofibromatosis-Noonan syndrome.
DR   PharmGKB; PA30587; -.
DR   eggNOG; KOG0581; Eukaryota.
DR   eggNOG; ENOG410XQ5A; LUCA.
DR   GeneTree; ENSGT00760000119199; -.
DR   HOGENOM; HOG000234206; -.
DR   HOVERGEN; HBG108518; -.
DR   InParanoid; P36507; -.
DR   KO; K04369; -.
DR   OMA; EGASEAH; -.
DR   OrthoDB; EOG091G0DEC; -.
DR   PhylomeDB; P36507; -.
DR   TreeFam; TF105137; -.
DR   BRENDA; 2.7.12.2; 2681.
DR   Reactome; R-HSA-112411; MAPK1 (ERK2) activation.
DR   Reactome; R-HSA-445144; Signal transduction by L1.
DR   Reactome; R-HSA-5210891; Uptake and function of anthrax toxins.
DR   Reactome; R-HSA-5673000; RAF activation.
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   Reactome; R-HSA-5674499; Negative feedback regulation of MAPK pathway.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802949; Signaling by RAS mutants.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF fusions.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   SignaLink; P36507; -.
DR   SIGNOR; P36507; -.
DR   ChiTaRS; MAP2K2; human.
DR   EvolutionaryTrace; P36507; -.
DR   GeneWiki; MAP2K2; -.
DR   GenomeRNAi; 5605; -.
DR   PMAP-CutDB; P36507; -.
DR   PRO; PR:P36507; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000126934; -.
DR   CleanEx; HS_MAP2K2; -.
DR   ExpressionAtlas; P36507; baseline and differential.
DR   Genevisible; P36507; HS.
DR   GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005769; C:early endosome; TAS:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; TAS:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005770; C:late endosome; TAS:UniProtKB.
DR   GO; GO:0005874; C:microtubule; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; TAS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; TAS:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005778; C:peroxisomal membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004708; F:MAP kinase kinase activity; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0030165; F:PDZ domain binding; IDA:UniProtKB.
DR   GO; GO:0043539; F:protein serine/threonine kinase activator activity; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:Reactome.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; TAS:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0097110; F:scaffold protein binding; IPI:UniProtKB.
DR   GO; GO:0004702; F:signal transducer, downstream of receptor, with serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0000187; P:activation of MAPK activity; TAS:UniProtKB.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; TAS:Reactome.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0010629; P:negative regulation of gene expression; IGI:UniProtKB.
DR   GO; GO:0036289; P:peptidyl-serine autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:BHF-UCL.
DR   GO; GO:1903800; P:positive regulation of production of miRNAs involved in gene silencing by miRNA; IMP:BHF-UCL.
DR   GO; GO:0071902; P:positive regulation of protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IMP:BHF-UCL.
DR   GO; GO:0035897; P:proteolysis in other organism; TAS:Reactome.
DR   GO; GO:2000641; P:regulation of early endosome to late endosome transport; TAS:UniProtKB.
DR   GO; GO:0090170; P:regulation of Golgi inheritance; TAS:UniProtKB.
DR   GO; GO:0032872; P:regulation of stress-activated MAPK cascade; TAS:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Cardiomyopathy;
KW   Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Disease mutation; Ectodermal dysplasia; Kinase; Magnesium; Membrane;
KW   Mental retardation; Metal-binding; Nucleotide-binding; Phosphoprotein;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase;
KW   Tyrosine-protein kinase.
FT   CHAIN         1    400       Dual specificity mitogen-activated
FT                                protein kinase kinase 2.
FT                                /FTId=PRO_0000086372.
FT   DOMAIN       72    369       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      78     86       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   COMPBIAS    266    315       Pro-rich.
FT   ACT_SITE    194    194       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     101    101       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE         10     11       Cleavage; by anthrax lethal factor.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:19413330}.
FT   MOD_RES      23     23       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     222    222       O-acetylserine; by Yersinia yopJ;
FT                                alternate. {ECO:0000269|PubMed:17116858}.
FT   MOD_RES     222    222       Phosphoserine; by RAF; alternate.
FT                                {ECO:0000269|PubMed:10409742,
FT                                ECO:0000269|PubMed:17116858}.
FT   MOD_RES     226    226       O-acetylserine; by Yersinia yopJ;
FT                                alternate. {ECO:0000269|PubMed:17116858}.
FT   MOD_RES     226    226       Phosphoserine; alternate.
FT                                {ECO:0000269|PubMed:17116858}.
FT   MOD_RES     293    293       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     295    295       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES     306    306       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q02750}.
FT   MOD_RES     394    394       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|Ref.3}.
FT   MOD_RES     396    396       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   VARIANT      57     57       F -> C (in CFC4; dbSNP:rs121434497).
FT                                {ECO:0000269|PubMed:16439621}.
FT                                /FTId=VAR_035095.
FT   VARIANT      57     57       F -> V (in CFC4; dbSNP:rs121434498).
FT                                {ECO:0000269|PubMed:18042262}.
FT                                /FTId=VAR_069781.
FT   VARIANT     128    128       P -> Q (in CFC4; results in increased
FT                                kinase activity; dbSNP:rs267607230).
FT                                {ECO:0000269|PubMed:20358587}.
FT                                /FTId=VAR_069782.
FT   VARIANT     134    134       Y -> H (in CFC4; dbSNP:rs121434499).
FT                                {ECO:0000269|PubMed:18042262}.
FT                                /FTId=VAR_069783.
FT   CONFLICT     56     56       A -> R (in Ref. 6; AA sequence).
FT                                {ECO:0000305}.
FT   HELIX        69     71       {ECO:0000244|PDB:1S9I}.
FT   STRAND       72     80       {ECO:0000244|PDB:1S9I}.
FT   STRAND       85     91       {ECO:0000244|PDB:1S9I}.
FT   TURN         92     94       {ECO:0000244|PDB:1S9I}.
FT   STRAND       97    103       {ECO:0000244|PDB:1S9I}.
FT   HELIX       110    119       {ECO:0000244|PDB:1S9I}.
FT   HELIX       120    122       {ECO:0000244|PDB:1S9I}.
FT   STRAND      133    148       {ECO:0000244|PDB:1S9I}.
FT   HELIX       155    161       {ECO:0000244|PDB:1S9I}.
FT   STRAND      162    164       {ECO:0000244|PDB:1S9I}.
FT   HELIX       167    186       {ECO:0000244|PDB:1S9I}.
FT   HELIX       197    199       {ECO:0000244|PDB:1S9I}.
FT   STRAND      200    202       {ECO:0000244|PDB:1S9I}.
FT   STRAND      208    210       {ECO:0000244|PDB:1S9I}.
FT   HELIX       217    222       {ECO:0000244|PDB:1S9I}.
FT   HELIX       236    239       {ECO:0000244|PDB:1S9I}.
FT   HELIX       246    262       {ECO:0000244|PDB:1S9I}.
FT   HELIX       272    279       {ECO:0000244|PDB:1S9I}.
FT   HELIX       318    327       {ECO:0000244|PDB:1S9I}.
FT   TURN        335    337       {ECO:0000244|PDB:1S9I}.
FT   HELIX       340    349       {ECO:0000244|PDB:1S9I}.
FT   TURN        354    356       {ECO:0000244|PDB:1S9I}.
FT   HELIX       360    364       {ECO:0000244|PDB:1S9I}.
FT   HELIX       367    374       {ECO:0000244|PDB:1S9I}.
FT   HELIX       379    386       {ECO:0000244|PDB:1S9I}.
SQ   SEQUENCE   400 AA;  44424 MW;  3401D522515C30A5 CRC64;
     MLARRKPVLP ALTINPTIAE GPSPTSEGAS EANLVDLQKK LEELELDEQQ KKRLEAFLTQ
     KAKVGELKDD DFERISELGA GNGGVVTKVQ HRPSGLIMAR KLIHLEIKPA IRNQIIRELQ
     VLHECNSPYI VGFYGAFYSD GEISICMEHM DGGSLDQVLK EAKRIPEEIL GKVSIAVLRG
     LAYLREKHQI MHRDVKPSNI LVNSRGEIKL CDFGVSGQLI DSMANSFVGT RSYMAPERLQ
     GTHYSVQSDI WSMGLSLVEL AVGRYPIPPP DAKELEAIFG RPVVDGEEGE PHSISPRPRP
     PGRPVSGHGM DSRPAMAIFE LLDYIVNEPP PKLPNGVFTP DFQEFVNKCL IKNPAERADL
     KMLTNHTFIK RSEVEEVDFA GWLCKTLRLN QPGTPTRTAV
//
